Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study
- PMID: 12205285
- PMCID: PMC4561177
- DOI: 10.1542/peds.110.3.e35
Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study
Abstract
Objective: To describe the extent of adherence to the recommended neonatal zidovudine (ZDV) regimen administered to infants who have been exposed to the human immunodeficiency virus (HIV) to prevent mother-to-child transmission of HIV and to determine which maternal factors are associated with compliance.
Methods: HIV-infected women (n = 87) who were participating in a larger study of perinatal transmission at 3 inner-city New York City hospitals were interviewed 2 to 6 weeks' postpartum to assess adherence to neonatal prophylaxis, social support, social network factors, and depression. In addition, plasma samples of 45 of their infants were assayed for ZDV levels.
Results: A majority of women (71%) administered all of the prescribed 4 daily doses in the previous week, as measured by interview; self-reported adherence was not associated with any maternal characteristics. In contrast, poor adherence, as measured by lower infant ZDV plasma levels, was associated with asymptomatic HIV illness in the mother and having 2 or more other children; good adherence, as indicated by higher ZDV levels, was associated with the presence of a maternal social support network, disclosure of HIV infection, and mothers' adherence to their own ZDV regimens during pregnancy. In multivariate regression analyses, maternal asymptomatic status (beta = -0.40) was associated with lower infant ZDV levels, and maternal adherence during pregnancy (beta = 0.37) was associated with higher levels.
Conclusions: Women who are HIV asymptomatic and lack a social support network are more likely not to comply with the recommended neonatal prophylactic regimen of antiretroviral therapy. Future studies should address the prenatal period and social network factors, such as disclosure of serostatus, and the custody of other children.
Similar articles
-
Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy.Women Health. 2005;42(1):99-115. doi: 10.1300/J013v42n01_06. Women Health. 2005. PMID: 16418124 Free PMC article. Clinical Trial.
-
Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort.Pediatrics. 2003 May;111(5 Pt 2):1186-91. Pediatrics. 2003. PMID: 12728136
-
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.JAMA. 2004 Jul 14;292(2):202-9. doi: 10.1001/jama.292.2.202. JAMA. 2004. PMID: 15249569 Clinical Trial.
-
Zidovudine.Infect Dis Obstet Gynecol. 1998;6(5):197-203. doi: 10.1002/(SICI)1098-0997(1998)6:5<197::AID-IDOG2>3.0.CO;2-1. Infect Dis Obstet Gynecol. 1998. PMID: 9894173 Free PMC article. Review.
-
Prevention of perinatal HIV transmission during pregnancy.J Antimicrob Chemother. 2000 Nov;46(5):657-68. doi: 10.1093/jac/46.5.657. J Antimicrob Chemother. 2000. PMID: 11062184 Review.
Cited by
-
Parenting Among Adolescents and Young Adults with Human Immunodeficiency Virus Infection in the United States: Challenges, Unmet Needs, and Opportunities.AIDS Patient Care STDS. 2016 Jul;30(7):315-23. doi: 10.1089/apc.2016.0067. AIDS Patient Care STDS. 2016. PMID: 27410495 Free PMC article. Review.
-
Adherence to high activity antiretrovial therapy (HAART) in pediatric patients infected with HIV: issues and interventions.Indian J Pediatr. 2007 Jan;74(1):55-60. doi: 10.1007/s12098-007-0028-8. Indian J Pediatr. 2007. PMID: 17264455 Review.
-
Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.Pediatrics. 2008 Apr;121(4):e787-93. doi: 10.1542/peds.2007-1586. Pediatrics. 2008. PMID: 18381507 Free PMC article.
-
Adherence to antiretroviral prophylaxis during early infancy in Latin America.Braz J Infect Dis. 2013 Jul-Aug;17(4):495-6. doi: 10.1016/j.bjid.2012.11.006. Epub 2013 May 13. Braz J Infect Dis. 2013. PMID: 23680065 Free PMC article. No abstract available.
-
Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done?Paediatr Drugs. 2005;7(3):137-49. doi: 10.2165/00148581-200507030-00002. Paediatr Drugs. 2005. PMID: 15977960 Review.
References
-
- Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180. - PubMed
-
- Centers for Disease Control and Prevention. Recommendations of the US Public Health Service task force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1994;43(RR-11):1–20. - PubMed
-
- Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–1414. - PubMed
-
- Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep. 1995;44(RR-7):1–15. - PubMed
-
- Centers for Disease Control and Prevention. Update: HIV counseling and testing using rapid tests-United States, 1995. MMWR Morb Mortal Wkly Rep. 1998;47:211–215. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical